Status:
COMPLETED
Serum Galectin-3 as a Marker of Human Papillomavirus Infection
Lead Sponsor:
Assiut University
Conditions:
Human Papillomavirus Infection
Eligibility:
All Genders
18-60 years
Brief Summary
This study aimed to assess the serum Galectin-3 levels in patients with warts both before and after cryotherapy and to investigate its potential contribution to the pathogenesis of human papillomaviru...
Detailed Description
Galectin-3 regulates many functions at the cellular level such as cell attachment, proliferation, and apoptosis. Numerous viral illnesses, including human papillomavirus infection, were reported to ha...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients with non-genital warts.
- Age of patients: from 18 to 60 years.
- Exclusion criteria:
- Patients with genital and mucosal warts.
- Pregnancy and breastfeeding.
- Patients who received any wart treatment during the last month before enrollment in the study.
Exclusion
Key Trial Info
Start Date :
December 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06005389
Start Date
December 1 2021
End Date
February 1 2023
Last Update
August 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut University
Asyut, Egypt, 71511